(Q38051013)

27 August 2017

title

Assessing the in vivo efficacy of biologic antiangiogenic therapies (English)

1 reference

27 August 2017

main subject

angiogenesis inhibitor

1 reference

3

Heinz-Josef Lenz

1 reference

27 August 2017

Peter M Wilson

1

1 reference

27 August 2017

Melissa J LaBonte

series ordinal

2

1 reference

27 August 2017

publication date

9 October 2012

1 reference

Cancer Chemotherapy and Pharmacology

27 August 2017

published in

1 reference

27 August 2017

volume

71

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

1-12

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1978-8

27 August 2017

exact match

0 references

cites work

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Vascular endothelial growth factor as a target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Molecular predictors of response to antiangiogenesis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGFs, receptors and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Resistance in the anti-angiogenic era: nay-saying or a word of caution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF spliced variants: possible role of anti-angiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF-B: a survival, or an angiogenic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

The discovery of the placental growth factor and its role in angiogenesis: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

PlGF blockade does not inhibit angiogenesis during primary tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Molecular imaging of akt enables early prediction of response to molecular targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1978-8

10.1007/S00280-012-1978-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1043202954

0 references

1 reference